-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sodium - glucose cotransporter 2 inhibitors may reduce hospitalization for heart failure and cardiac vascular deaths, although the underlying mechanism is not yet clear
.
Recently, an authoritative journal in the field of cardiovascular diseases published a research article on the effect of empagliflozin on myocardial blood flow reserve in type 2 diabetic patients (SIMPLE test), which analyzed the effect of empagliflozin on type 2 with high risk of cardiovascular disease Diabetes patients reflect the influence of microvascular perfusion-myocardial blood flow reserve (MFR)
.
Researchers randomly assigned 90 patients to 25 mg of empagliflozin, once a day or placebo for 13 weeks
.
The main outcome of the study was the change in MFR at week 13, quantified by rubidium 82 positron emission tomography/computed tomography
The average change of PET/CT parameters after 13 weeks of treatment with empagliflozin
The average baseline MFR of subjects was 2.
21 (95% CI 2.
08-2.
35)
.
It was 0.
It can be seen that empagliflozin did not improve the MFR of patients with type 2 diabetes with high cardiovascular risk
.
The study does not support the use of short-term improvements in MFR to explain the reduction in cardiovascular events observed in the outcome trial
Enpagliflozin did not improve the MFR of patients with type 2 diabetes with high cardiovascular risk
Original source:
Mikkel Jürgens.
